WRAL Tech Wire

Safer aspirin from Pozen accepted for FDA review

An FDA approval decision on Pozen's PA drug could come by early January.

 AstraZeneca's decision to stop pain drug's promotion leaves Pozen considering new partners

AstraZeneca's decision to stop promoting arthritis drug Vimovo in key markets leaves drug partner Pozen figuring out its options for what is currently its top-selling product. What might the company do?

How Vimovo works

 Pozen's painful partner news triggers 15% drop in stock price

Shares plunged Wednesday after the Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen?

 Latest pain for Pozen: AstraZeneca to stop sales of its pain reliever in US

The Chapel Hill-based pharmaceutical firm discloses in its quarterly financial report that a big drug partner is going to stop selling the company's big money maker in the U.S. and parts of Europe. What does this mean for Pozen and its shareholders?

 Safer aspirin from Pozen filed for FDA approval

A safer-on-the-stomach aspirin developed by Pozen has been submitted to the Food and Drug Administration for regulatory approval

 Pozen's drug combination patent maintained in Europe

European patents for Pozen's combination drug technology are valid and will continue to stand, according to a decision issued by European patent authorities.

 Pozen pain reliever sales, royalties surge in 2012

Sales of Vimovo, a pain reliever sold by partner AstraZeneca, surged in 2012, thus delivering a growing revenue stream to Chapel Hill-based Pozen. But the company still posted a $25 million dollar loss.

 Earnings: Salix; PowerSecure; Pozen; BioCryst

Inside the Bulldog Blog: Revenues up at Salix; record revenues for PowerSecure; Pozen cuts losses; net loss declines at Biocryst;

 Pozen reports positive test results for proposed aspirin therapy

Results from two Phase 3 clinical trials for its proposed aspirin therapy are positive, Chapel Hill-based Pozen says.

 Pozen prevails in patent fight over pain killer

The Chapel Hill-based pharmaceutical firm has already sold future royalty rights and milestone payments that it would have received from GlaxoSmithKline for $75 million.

 Pozen won't need new trial for proposed safer aspirin

After discussions with the FDA, the Chapel Hill-based drug firm says its safer form of aspirin could be ready for a drug filing in the first half of 2013.

 Pozen secures second patent for its drug technology

 FDA wants more tests on proposed Pozen heart drug

The Chapel Hill drug developer says the FDA wants more information on PA32540, an aspirin combination drug developed to deliver the cardiovascular benefits of aspirin in a way less likely to cause stomach irritation characteristic of aspirin alone.

 Pozen migraine drug licensed to Desitin for commercialization in Europe

The migraine headache treatment developed by Pozen now has a partner for commercialization in Europe.

 Pozen losses increase but arthritis drug royalties grow

The Chapel Hill-based drug firm reports a loss of $8.4 million for the first quarter, up from $5.7 million a year ago. However, sales of the arthirtis drug Vimovo are growing.

 Pozen runs into a headache with FDA over safer aspirin

During a recent meeting with the FDA to discuss its submission, the agency suggested the Chapel Hill-based company also seek approval for the drug at a lower dose

 Pozen shares surge on aspirin therapy trial news

The Chapel Hill-based pharmaceutical firm says its compound redcues gastric ulcers in two Phase 3 trials of patients who are taking aspirin daily. Pozen plans a new drug application in the third quarter. PLUS: Two board memebers leaving.

Diagram from Pozen presentation about PA technology

 Pozen strikes manufacturing pact with Patheon for heart drug

Pozen's new cardiovascular drug does not even have a name yet, but it has a manufacturer to produce it once it gets U.S. Food and Drug Administration approval.

 Pozen's $75M deal - It's all about cash for product pipeline

The money strengthens Pozen's negotiating position as it seeks a partner for a drug under development and does so without diluting Pozen's shareholders, CEO John Platchetka

 Pozen sells royalty rights to migraine drug for $75M

Treximet is marketed in the United States by Pozen drug partner GlaxoSmithKline. The royalty rights were purchased by a Canadian pension plan.